

GenCore Version 5.1.3
Copyright (c) 1993 - 2003 CompuGen Ltd

OM protein - protein search, using sw model

Run on: January 16, 2003, 16:34:47 : Search time 66.6 seconds
(without alignments)
28.011 Million cell updates/sec

Title: US-09-856-070-17

Perfect score: 69

Sequence: 1 FKEWEQMMKEKHL 14

Scoring table:

BLOSUM62

Gapop 10.0 : Gapext 0.5

Searched: 908470 seqs, 131250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0

Maximum DB seq length: 2600000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- 1: /SID52/qcqlata/geneseq/geneseq-emb1/AA1980.DAT:*
- 2: /SID52/qcqlata/geneseq/geneseq-emb1/AA1981.DAT:*
- 3: /SID52/qcqlata/geneseq/geneseq-emb1/AA1982.DAT:*
- 4: /SID52/qcqlata/geneseq/geneseq-emb1/AA1983.DAT:*
- 5: /SID52/qcqlata/geneseq/geneseq-emb1/AA1984.DAT:*
- 6: /SID52/qcqlata/geneseq/geneseq-emb1/AA1985.DAT:*
- 7: /SID52/qcqlata/geneseq/geneseq-emb1/AA1986.DAT:*
- 8: /SID52/qcqlata/geneseq/geneseq-emb1/AA1987.DAT:*
- 9: /SID52/qcqlata/geneseq/geneseq-emb1/AA1988.DAT:*
- 10: /SID52/qcqlata/geneseq/geneseq-emb1/AA1989.DAT:*
- 11: /SID52/qcqlata/geneseq/geneseq-emb1/AA1990.DAT:*
- 12: /SID52/qcqlata/geneseq/geneseq-emb1/AA1991.DAT:*
- 13: /SID52/qcqlata/geneseq/geneseq-emb1/AA1992.DAT:*
- 14: /SID52/qcqlata/geneseq/geneseq-emb1/AA1993.DAT:*
- 15: /SID52/qcqlata/geneseq/geneseq-emb1/AA1994.DAT:*
- 16: /SID52/qcqlata/geneseq/geneseq-emb1/AA1995.DAT:*
- 17: /SID52/qcqlata/geneseq/geneseq-emb1/AA1996.DAT:*
- 18: /SID52/qcqlata/geneseq/geneseq-emb1/AA1997.DAT:*
- 19: /SID52/qcqlata/geneseq/geneseq-emb1/AA1998.DAT:*
- 20: /SID52/qcqlata/geneseq/geneseq-emb1/AA1999.DAT:*
- 21: /SID52/qcqlata/geneseq/geneseq-emb1/AA2000.DAT:*
- 22: /SID52/qcqlata/geneseq/geneseq-emb1/AA2001.DAT:*
- 23: /SID52/qcqlata/geneseq/geneseq-emb1/AA2002.DAT:*

pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	69	100.0	14	23	AA82035 Human hepreceptor
2	69	100.0	436	23	AA87094 Human colony cancer
3	69	100.0	586	20	AA27443 Amino acid sequence
4	69	100.0	522	22	AA03004 Novel human secret
5	69	100.0	635	21	AA85356 Human colon cancer
6	51	73.9	503	22	AA81657 Novel human diango
7	51	73.9	593	22	ABG1947 Novel human diango
8	49	71.0	52	22	AA03060 Novel human secret
9	47	68.1	357	22	AA01645 Human novel secret
10	47	68.1	472	22	AA016019 Human novel secret

11	47	68.1	484	21	AA42228 Human GRFX GRF1992
12	47	68.1	580	22	AA42158 Human polypeptide
13	47	68.1	580	22	AA42158 Human polypeptide
14	47	68.1	690	22	AA895603 Human protein sequ
15	47	68.1	691	22	AA40372 Human polypeptide
16	47	68.1	691	22	AA012179 Human PRO4996 poly
17	47	68.1	691	23	AB07265 Human APRC polypep
19	47	68.1	711	22	AA40373 Human polypeptide
20	47	68.1	1072	22	AA670871 C albicans apoptos
21	46	66.7	2274	22	AA670871 C albicans apoptos
22	46	66.7	75	23	ABP31093 Human GRF66 protei
23	46	66.7	586	22	AA012194 Human PRO4987 poly
24	46	66.7	586	23	AAH77445 Human tumour marke
25	46	66.7	586	23	AAH77445 Human tumour marke
26	46	66.7	633	19	AA44892 Human quanylate bi
27	45	65.2	721	22	AB62213 Lrosophila melanoq
28	44	63.8	374	21	AA008101 Novel human diango
29	44	63.8	793	22	AA029389 Arabidopsis thalia
30	43	62.3	87	22	AAH76980 Human inverted DCA
31	43	62.3	87	22	AAH76980 Human inverted DCA
32	43	62.3	98	22	AA016587 Human reproductive
33	43	62.3	98	22	AA016587 Human reproductive
34	43	62.3	98	22	AA016587 Human reproductive
35	43	62.3	98	22	AA016587 Human reproductive
36	43	62.3	121	22	AA016172 Human novel secret
37	43	62.3	179	22	AA074288 Human colon cancer
38	43	62.3	289	22	AA093619 Human protein sequ
39	43	62.3	301	8	AA070867 sequence of acidic
40	43	62.3	354	21	AA42527 Human GRFX GRF291
41	43	62.3	354	22	AAH71628 Lrosophila melanoq
42	43	62.3	513	22	AA42527 Human polypeptide
43	43	62.3	513	22	AA42527 Human polypeptide
44	43	62.3	533	22	AA063453 Human cell cycle a
45	43	62.3	567	22	AA013147 Human retinilis pi
46	43	62.3	740	13	AA670936 Plasmodium falcipa

ALIGNMENTS

RESULT 1

AAH82035

ID AAH82035 standard, peptide: 14 AA.

XX AAH82035;

XX 13-JUN 2001 (first entry)

XX human hepreceptor domain A/H binding peptide R401024.

XX Human, hepreceptor; cytostatic, anti-HIV, antibiotic;

XX oncogenic, immune response inducer, ezrin; infectious diseases: cancer;

XX HIV-related dementia.

XX Homo sapiens.

XX GB2354241-A.

XX 21-MAR-2001.

XX 17-SEP-1999; 99GB-0021881.

XX 17-SEP-1999; 99GB-0021881.

XX (HOLM/) HOLMS R D.

XX Holms RD;

XX WPI: 2001 200287/31

XX Novel regulatory or modulating peptides of ezrin that binds to

XX hepreceptor; useful for inducing immune response for treating

XX infectious diseases and cancer .

XX Claim 20; Page 36; 42pp; English.

XX The hepreceptor is a novel active site in human ezrin. Ezrin regulates

XX the structure of the cortical cytoskeleton to control cell surface

XX topography. The present invention relates to peptides (see AAB82021 to

XX AAB82041) that bind to hepreceptor with greater affinity than HEP1 (see

XX AAB82046). The hepreceptor binding peptides are useful for inducing

XX immune response, and for treating infectious diseases, cancer and

XX HIV-related dementia. The present peptide binds to domains A and B of the

XX hepreceptor (AAB82039 and AAB82020).

XX Sequence 14 AA:

Query Match 100.0%; Score 69; DH 22; Length 14;

Best Local Similarity 100.0%; Pred. No. 0.00073;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EREKEQMMREKEEL 14

DB 1 EREKEQMMREKEEL 14

RESULT 2

AA673954

1b AAG73954 standard; Protein: 436 AA.

XX AAG73954;

DT 03-SEP-2001 (first entry)

DE Human colon cancer antigen protein SEQ ID NO:4718.

KW Human; colon cancer; colon cancer antigen; diagnosis; detection,

KW colorectal carcinoma.

OS Homo sapiens.

XX WO200122920 A2.

XX 05-APR-2001.

XX 28-SEP-2000; 2000WO-US-0524.

XX 29-SEP-1999; 99US-0157137.

XX 03-NOV-1999; 99US-0163280.

XX (HUMA-) HUMAN GENOME SCI INC.

XX Ruben SM, Barash SC, Birse CE, Rosen CA;

XX WPI; 2001 245357/24.

XX N-PSDB; AAB33485.

XX Nucleic acids encoding 4277 human colon cancer-associated polypeptides,

XX useful for preventing, diagnosing and/or treating colorectal cancers.

XX Claim 11; Page 6520-6521; 9803pp; English.

XX AAB32043 to AAB37196 and AAB37514 to AAB77789 represent human colon

XX cancer-associated nucleic acid molecules (N) and proteins (P), where

XX the proteins are collectively known as colon cancer antigens. The colon

XX cancer antigens have cytostatic activity and can be used in gene

XX therapy and vaccine production. N and P may be used in the prevention,

XX diagnosis and treatment of diseases associated with inappropriate p

XX expression. For example, N and P may be used to treat disorders

XX associated with decreased expression by rectifying mutations or deletions

XX in a patient's genome that affect the activity of P by expressing

XX inactive proteins or to supplement the patients own production of P.

XX Additionally, N may be used to produce the colon cancer-associated Ps,

XX by inserting the nucleic acids into a host cell and culturing the cell

XX to express the proteins. N and P can be used in the prevention, diagnosis

XX and treatment of colorectal carcinomas and cancers AAB37196 to AAB37204

CC and AAB77789 represent sequences used in the exemplification of the

CC present invention.

CC N & pages 466 to 482 and page 7053 of the sequence listing were

CC missing at time of publication, meaning to sequences are present for

XX SEQ ID NO:1027 to 1052, 7921 and 7922.

XX Sequence 436 AA;

Query Match 100.0%; Score 69; DH 22; Length 436;

Best Local Similarity 100.0%; Pred. No. 0.024;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EREKEQMMREKEEL 14

DB 184 EREKEQMMREKEEL 197

RESULT 3

AA27443

ID AAY27443 standard; protein: 586 AA.

XX AC AAY27443;

XX 26-NOV-1999 (first entry)

XX Amino acid sequence of human ezrin polypeptide.

XX Pharmaceutical; ezrin; mutant; tumor; metastasis; human.

XX Homo sapiens.

XX Key Location/Qualifiers

XX Misc difference 354

XX /note- "the 1yr at this position can be mutated

XX (preferably to a phe) to construct an

XX ezrin mutant of the invention"

XX WO9947150-A2.

XX 23-SEP-1999.

XX 18-MAR-1999; 99WO-EP02054.

XX 18-MAR-1998; 98US-0040725

XX (CURT-) INST CURIE.

XX (CNRS) CNRS CENT NAT RECH SCI.

XX Arpin M, Crepaldi T, Gautreau A, Louvard D;

XX WPI; 1999-561851/47.

XX New composition for prevention and treatment of tumors and metastasis

XX Example 1; Fig 1; 31pp; English.

XX The invention provides a pharmaceutical composition containing ezrin

XX protein, RNA or DNA mutated on tyrosine 353, or a functional fragment

XX or derivative of the ezrin mutant. The new composition is useful for

XX prevention and/or treatment of tumors, and especially metastasis. The

XX present sequence represents the amino acid sequence of human ezrin

XX (before the mutation by deletion of the first amino acid Met).

XX Sequence 586 AA;

Query Match 100.0%; Score 69; DH 20; Length 586;

Best Local Similarity 100.0%; Pred. No. 0.033;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EREKEQMMREKEEL 14

DB 334 EREKEQMMREKEEL 347

RESULT 4
AAU30004
ID AAU30004 standard; Protein: 622 AA.
XX
AC AAU30004;
XX
DT 18-DEC-2001 (first entry)
XX
DE Novel human secreted protein #495.
XX
KW Human, vaccination; gene therapy; nutritional supplement;
KW stem cell proliferation; haematopoiesis; nerve tissue regeneration;
KW immune suppression, immune stimulation, anti-inflammatory, leukaemia.
XX
OS Homo sapiens.
XX
PN W0200170444-A2
XX
PD 25-OCT-2001.
XX
PF 16-APR-2001; 2001WO-050865G.
XX
PP 18-APR-2000; 2000US 0552929.
PR 26-JAN-2001; 2001US-0770160.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Drmanac RT,
XX WPI: 2001-611725/70.
DR
XX Nucleic acids encoding a range of human polypeptides, useful in genetic
PT vaccination, testing and therapy -
XX
PS Claim 20, Page 219, 765pp, English.
XX
CC The invention relates to novel human secreted polypeptides. The
CC polypeptides and antibodies to the polypeptides are useful for
CC determining the presence of or predisposition to a disease associated
CC with altered levels of polypeptide. The polypeptides are also useful for
CC identifying agents (agonists and antagonists) that bind to them. Cells
CC expressing the proteins are useful for identifying a therapeutic agent
CC for use in treatment of a pathology related to aberrant expression or
CC physiological interactions of the polypeptide. Vectors comprising
CC the nucleic acids encoding the polypeptides and cells genetically
CC engineered to express them are also useful for producing the proteins.
CC The proteins are useful in genetic vaccination, testing and
CC therapy, and can be used as nutritional supplements. They may be used to
CC increase stem cell proliferation; to regulate haematopoiesis; and in
CC bone, cartilage, tendon and/or nerve tissue growth or regeneration;
CC immune suppression and/or stimulation; as anti-inflammatory agents; and
CC in treatment of leukaemias. AAU29510-AAU33304 represent the amino acid
XX sequences of novel human secreted proteins of the invention.
SQ Sequence 622 AA;
Query Match 100.0%; Score 69; DR 02; Length 622;
Best Local Similarity 100.0%; Pred. No. 0.035;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 EREKQMMPEKEEL 14
Db 370 EREKQMMPEKEEL 383
RESULT 5
AAB53356
ID AAB53356 standard; Protein: 635 AA
XX
AC AAB53356;
XX

DT 09-MAR-2001 (first entry)
XX
DE Human colon cancer antigen protein sequence SEQ ID NO:896.
XX
KW Human; Colon cancer, colon cancer antigen, diagnosis; detection;
KW identification, cytostatic, cardioactive, neuroprotective, vulnerary;
KW immunomodulatory; muscular, gynaecological, gastrointestinal;
KW nephrotropic; anti-infective, antibacterial, gene therapy; wound;
KW neural disorder; immune system disorder; muscular disorder;
KW reproductive disorder; gastrointestinal disorder; renal disorder;
KW infectious disease; cardiovascular disorder.
XX
OS Homo sapiens.
XX
PN W0200055351-A1.
XX
PD 21-SEP-2000.
XX
PF 08 MAR 2000; 2000WO US05883.
XX
PP 12-MAR-1999; 99US-0124270.
PR (HOMA-) HUMAN GENOME SCI INC.
XX
PA Posen CA, Ruben SM;
XX WPI: 2000-587534/55
DR N-PSDB; AAC98113.
XX
PT Colon cancer associated gene sequences, referred to as colon cancer
PT antigens, useful for the treatment, prevention, and diagnosis of colon
PT disorders such as colon cancer -
XX
PS Claim 11, Page 1449-1451, 2104pp, English.
XX
CC AAC97991 to AAC98763 encode the human colon cancer associated proteins,
CC called human colon cancer antigens, given in AAF53234 to AAB54006. The
CC human colon cancer antigens can have cytostatic, cardioactive, muscular;
CC neuroprotective, immunomodulatory, gynaecological, gastrointestinal,
CC vulnerary, nephrotropic, anti-infective and antibacterial activities, and
CC can be used in gene therapy. The colon cancer antigen polynucleotides,
CC proteins and antibodies to the proteins are useful for the prevention,
CC treatment and diagnosis of colon disorders, such as colon cancer. The
CC polynucleotides may be used in diagnostics and research, such as for
CC chromosome identification, and as hybridisation probes. The proteins
CC may also be used to prevent diseases such as neural disorders, immune
CC system disorders, muscular disorders, reproductive disorders,
CC gastrointestinal disorders, wounds, renal disorders, infectious
CC diseases, and cardiovascular disorders. AAC98764 to AAC98772 and
CC AAB54007 represent sequences used in the exemplification of the present
CC invention.
SQ Sequence 635 AA;
Query Match 100.0%; Score 69; DR 21; Length 635;
Best Local Similarity 100.0%; Pred. No. 0.036;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 EREKQMMPEKEEL 14
Db 383 EREKQMMPEKEEL 396
RESULT 6
ABG16577
ID ABG16577 standard; Protein: 503 AA.
XX
AC ABG16577;
XX
PT 18 FEB 2002 (first entry)
XX
DE Novel human diagnostic protein #16568.
XX

KW Human: chromosome mapping; gene mapping; gene therapy; forensic;
 KW food supplement; medical imaging; diagnostic; genetic disorder.
 XX
 OS Homo sapiens.
 XX
 PN WO200175067-A2.
 XX
 PD 11-OCT-2001.
 XX
 PF 30-MAR-2001; 2001WO-US08631
 XX
 PR 31-MAR-2000; 2000US-0540217.
 XX
 PR 23-AUG-2000; 2000US-0649167.
 XX
 PA (HYSE-) HYSEQ INC.
 XX
 PI Drmanac RT, Liu C, Tang YT;
 XX
 PI WPI: 2001-639362/73.
 XX
 DR N-PSDB: AAS80764.
 XX
 PT New isolated polynucleotide and encoded polypeptides, useful in
 PT diagnostics, forensics, gene mapping, identification of mutations
 PT responsible for genetic disorders or other traits and to assess
 PT biodiversity
 XX
 PS Claim 20: SEQ ID No 46936; 103pp; English.
 XX
 CC The invention relates to isolated polynucleotide (I) and
 CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
 CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
 CC and gene mapping, and in recombinant production of (II). The
 CC polynucleotides are also used in diagnostics as expressed sequence tags
 CC for identifying expressed genes. (I) is useful in gene therapy techniques
 CC to restore normal activity of (II) or to treat disease states involving
 CC (II). (II) is useful for generating antibodies against it, detecting or
 CC quantitating a polypeptide in tissue, as molecular weight markers and as
 CC a food supplement. (II) and its binding partners are useful in medical
 CC imaging of sites expressing (II). (I) and (II) are useful for treating
 CC disorders involving aberrant protein expression or biological activity.
 CC The polypeptide and polynucleotide sequences have applications in
 CC diagnostics, forensics, gene mapping, identification of mutations
 CC responsible for genetic disorders or other traits to assess biodiversity
 CC and to produce other types of data and products dependent on DNA and
 CC amino acid sequences. ABG00010-ABG30377 represent novel human
 CC diagnostic amino acid sequences of the invention.
 CC Note: The sequence data for this patent did not appear in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences.

.. SQ Sequence 503 AA;
 Query Match 73.9%; Score 51; DH 22; Length 503;
 Best Local Similarity 71.4%; Pred. No. 11;
 Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1 EREKQMMREKEEL 14
 I:||||:|||||
 Db 254 EREKTEREKEEL 267

RESULT 7
 ID ABG19947
 XX ABG19947 standard; Protein: 593 AA.
 AC
 XX ABG19947;
 XX
 DT 18 FEB-2002 (first entry)
 XX
 DE Novel human diagnostic protein #19938.

KW Human: chromosome mapping; gene mapping; gene therapy; forensic;
 KW food supplement; medical imaging; diagnostic; genetic disorder.

XX
 OS Homo sapiens.
 XX
 PN WO200175067-A2.
 XX
 PD 11-OCT-2001.
 XX
 PF 30-MAR-2001; 2001WO-US08631
 XX
 PR 31-MAR-2000; 2000US-0540217.
 XX
 PR 23-AUG-2000; 2000US-0649167.
 XX
 PA (HYSE-) HYSEQ INC.
 XX
 PI Drmanac RT, Liu C, Tang YT;
 XX
 PI WPI: 2001-639362/73.
 XX
 DR N-PSDB: AAS84134.
 XX
 PT New isolated polynucleotide and encoded polypeptides, useful in
 PT diagnostics, forensics, gene mapping, identification of mutations
 PT responsible for genetic disorders or other traits and to assess
 PT biodiversity
 XX
 PS Claim 20: SEQ ID No 50306; 103pp; English.
 XX
 CC The invention relates to isolated polynucleotide (I) and
 CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
 CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
 CC and gene mapping, and in recombinant production of (II). The
 CC polynucleotides are also used in diagnostics as expressed sequence tags
 CC for identifying expressed genes. (I) is useful in gene therapy techniques
 CC to restore normal activity of (II) or to treat disease states involving
 CC (II). (II) is useful for generating antibodies against it, detecting or
 CC quantitating a polypeptide in tissue, as molecular weight markers and as
 CC a food supplement. (II) and its binding partners are useful in medical
 CC imaging of sites expressing (II). (I) and (II) are useful for treating
 CC disorders involving aberrant protein expression or biological activity.
 CC The polypeptide and polynucleotide sequences have applications in
 CC diagnostics, forensics, gene mapping, identification of mutations
 CC responsible for genetic disorders or other traits to assess biodiversity
 CC and to produce other types of data and products dependent on DNA and
 CC amino acid sequences. ABG00010-ABG30377 represent novel human
 CC diagnostic amino acid sequences of the invention.
 CC Note: The sequence data for this patent did not appear in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences.

.. SQ Sequence 593 AA;

Query Match 73.9%; Score 51; DH 22; Length 593;
 Best Local Similarity 71.4%; Pred. No. 13;
 Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1 EREKQMMREKEEL 14
 I:||||:|||||
 Db 349 EREKTEREKEEL 362

RESULT 8
 ID AAU33060
 XX AAU33060 standard; Protein: 52 AA.
 AC
 XX AAU33060;
 XX
 DT 18-DEC-2001 (first entry)
 XX
 DE Novel human secreted protein #3551.

KW Human: vaccination; gene therapy; nutritional supplement;
 KW stem cell proliferation; haematopoiesis; nerve tissue regeneration;
 KW immune suppression; immune stimulation; anti-inflammatory; leukaemia.
 XX

XX Claim 11: SEQ ID NO 972: 980pp; English.

XX The invention relates to isolated nucleic acid molecules and their

XX encoded secreted proteins. The nucleic acids and proteins are used to

XX prevent, treat or ameliorate a medical condition in e.g. humans, mice,

XX rabbits, goats, horses, cats, dogs, chickens or sheep. They

XX are also used in diagnosing a pathological condition or susceptibility

XX to a pathological condition. Antibodies to the proteins can also

XX be used in alleviating symptoms associated with the disorders and in

XX diagnostic immunoassays e.g. radioimmunoassays or enzyme linked

XX immunosorbent assays (ELISA). Disorders which are diagnosed or treated

XX include autoimmune diseases e.g. rheumatoid arthritis,

XX hyperproliferative disorders e.g. neoplasms of the breast or liver,

XX cardiovascular disorders e.g. cardiac arrest, cerebrovascular disorders

XX e.g. cerebral ischaemia, angiogenesis, nervous system disorders e.g.

XX Alzheimer's disease, infections caused by bacteria, viruses and fungi

XX and ocular disorders e.g. corneal infection, and many other

XX disorders listed in the specification. The polypeptides can also

XX be used to aid wound healing and epithelial cell proliferation, to

XX prevent skin aging due to sunburn, to maintain organs before

XX transplantation, for supporting cell culture of primary tissues, to

XX regenerate tissues and in chemotaxis. The polypeptides can also be used

XX as a food additive or preservative to increase or decrease storage

XX capabilities, fat content, lipid, protein, carbohydrate, vitamins,

XX minerals, cofactors and other nutritional components. The present

XX sequence represents a novel secreted protein of the invention.

Query Match 68.1% Score 47; DB 22; Length 472;

Best Local Similarity 57.1% Pred. No. 40;

Matches 8; Conservative 4; Mismatches 2; Indels 0; Gaps 0.

QY 1 EREKEQMMREKEEL 14

DB 188 QKEKEQLQEEKQEL 201

RESULT 11

AA842228

ID AAB42228 standard; Protein, 484 AA.

XX AA842228

XX 08-FEB-2001 (first entry)

XX Human ORFX OPF1992 polypeptide sequence SEQ ID NO:3984.

XX Human; open reading frame; ORFX; detection; cytostatic; hepatotropic;

XX vulnervary; antiproliferative; antiparkinsonian; neurotropic; neuroprotective;

XX anticonvulsant; osteopathic; antiarthritis; immunosuppressant; cardiac;

XX immunostimulant; thrombolytic; coagulant; vasodilator; antidiabetic;

XX hypotensive; dermatological; immunosuppressive; antiinflammatory;

XX antiviral; antibacterial; antifungal; antirheumatic; antithyroid;

XX antianemic; gene therapy; cancer; proliferative disorder; hypertension;

XX neurodegenerative disorder; osteoarthritis; graft vs host disease;

XX cardiovascular disease; diabetes mellitus; hypothyroidism; SCID; AIDS;

XX cholesterol ester storage; systemic lupus erythematosus; infection;

XX severe combined immunodeficiency; malaria; autoimmune disorder; asthma;

XX allergy; aplastic anaemia; nocturnal haemoglobinuria; burn; wound;

XX bone damage; cartilage damage; antiinflammatory disease; coagulation;

XX thrombosis; contraceptive.

XX Homo sapiens

XX W0200058473-A2.

XX 05-OCT-2000.

XX 31-MAR-2000; 2000WO-US08621.

XX 31-MAR-1999; 99US-0127607.

XX 02-APR-1999; 99US-0127636.

XX 05-APR-1999; 99US-0127728.

PR 30-MAR-2000; 2000US-0540763.

XX (CURA-) CURAGEN CORP.

XX Shimkels RA, Leach M;

XX WPI: 2000 602362/57.

XX N-PSDB; AAC76437.

XX Novel nucleic acids and peptides derived from open reading frame X,

XX useful for treating e.g. cancers, proliferative disorders,

XX neurodegenerative disorders and cardiovascular disease -

XX Claim 11; Page 3150 3152; 5507pp; English.

XX AAC74446 to AAC7506 encode the proteins given in AAB40237 to AAB43397,

XX which represent the human ORFX open reading frames 1 to 161. The ORFX

XX sequences have activities such as: cytostatic; hepatotropic; vulnervary;

XX antiproliferative; antiparkinsonian; neurotropic; neuroprotective;

XX osteopathic; anticonvulsant; antiarthritis; immunosuppressant;

XX immunostimulant; cardiac; thrombolytic; coagulant; vasodilator;

XX antidiabetic; hypotensive; dermatological; immunosuppressive;

XX antiinflammatory; antibacterial; antiviral; antifungal; antirheumatic;

XX antithyroid; and antianemic. The sequences can be used for determining

XX the presence of or predisposition to, or preventing or treating

XX pathological conditions associated with an ORFX-associated disorder. The

XX nucleic acids can be used to express ORFX proteins in gene therapy

XX vectors. The proteins and nucleic acids may be used to treat cancers,

XX proliferative disorders, neurodegenerative disorders, osteoarthritis,

XX graft vs host disease, cardiovascular disease, diabetes mellitus,

XX hypertension, hypothyroidism, cholesterol ester storage, systemic lupus

XX erythematosus, severe combined immunodeficiency (SCID), AIDS, viral,

XX bacterial or fungal infection, malaria, autoimmune disorders, asthma,

XX allergies, aplastic anaemia, burns, wounds, bone and cartilage damage,

XX nocturnal haemoglobinuria, antiinflammatory disease; to enhance

XX coagulation, to inhibit thrombosis; and as a contraceptive.

XX Sequence 484 AA;

Query Match 68.1% Score 47; DB 21; Length 484;

Best Local Similarity 57.1% Pred. No. 41;

Matches 8; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1 EREKEQMMREKEEL 14

DB 276 QKEKEQLQEEKQEL 289

RESULT 12

AA842158

ID AAM42158 standard; Protein, 580 AA.

XX AA842158;

XX 22-OCT-2001 (first entry)

XX Human polypeptide SEQ ID NO 7089.

XX Human; neurotropic; immunosuppressant; cytostatic; gene therapy; cancer;

XX peripheral nervous system; neuropathy; central nervous system; CNS;

XX Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;

XX amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;

XX chemokinetic; thrombolytic; drug screening; arthritis; inflammation;

XX leukaemia.

XX Homo sapiens.

XX W0200153312-A1.

XX 26-JUL-2001.

XX 26 DEC 2000; 2000WO US34263.

PR 21-JAN-2000: 2000US-0488725.
 PP 25-APR-2000: 2000US-057317.
 PP 09-JUL-2000: 2000US-0598042.
 PP 19-JUL-2000: 2000US-0620310.
 PP 03-AUG-2000: 2000US-0654450.
 PR 14-SEP-2000: 2000US-0662101.
 PR 19-OCT-2000: 2000US-0684036.
 PR 25-NOV-2000: 2000US-0727344.
 XX (HYSE-) HYSEQ INC.
 XX Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
 PI Wang J, Wang Z, Wehrman T, Xu C, Xue AZ, Yang Y, Zhang J;
 PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
 XX WPI: 2001-442253/47.
 DE N-PSDB: AAI61315.
 XX Novel nucleic acids and polypeptides useful for treating disorders
 PT such as central nervous system injuries.
 PS Example 2: SEQ ID NO 7089; 10078pp, English.
 XX The invention relates to human nucleic acids (AA157798-AA161369) and
 CC the encoded polypeptides (AA158642-AA162219) with nucleotide
 CC immunosuppressant and cytostatic activity. The polynucleotides are useful
 CC in gene therapy. A composition containing a polypeptide or polynucleotide
 CC of the invention may be used to treat diseases of the peripheral nervous
 CC system, such as peripheral nervous injuries, peripheral neuropathy and
 CC localised neuropathies and central nervous system diseases, such as
 CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
 CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
 CC utilisation of the activities such as: Immune system suppression,
 CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
 CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
 CC assays for receptor activity, arthritis and inflammation, leukaemias and
 CC C.N.S disorders.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification.
 SQ Sequence 580 AA;
 Query Match 68.1%; Score 47; DB 22; Length 580;
 Best Local Similarity 57.1%; Pred. No. 50;
 Matches 8; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 QY 1 EREKQMMREKEEL 14
 Db 495 QREKEQLQEKQEL 508
 RESULT 13
 AAM42159
 ID AAM42159 standard; Protein: 580 AA.
 XX AAM42159;
 AC AAM42159;
 DI 22-OCT-2001 (first entry)
 XX Human polypeptide SEQ ID NO 7090.
 DE Human, non replic, immunosuppressant, cytostatic; gene therapy; cancer;
 XX peripheral nervous system; neuropathy; central nervous system; CNS;
 KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
 KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
 KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
 KW leukaemia.
 XX Homo sapiens.
 OS Homo sapiens.
 PN WO200153312-A1.
 XX 26-JUL-2001
 PD

XX CC EEC 2000: 2000US-0541663.
 XX 21-JAN-2000: 2000US-0488725.
 PR 25-APR-2000: 2000US-057317.
 PR 09-JUL-2000: 2000US-0598042.
 PR 19-JUL-2000: 2000US-0620310.
 PR 03-AUG-2000: 2000US-0654450.
 PR 14-SEP-2000: 2000US-0662101.
 PR 19-OCT-2000: 2000US-0684036.
 PR 25-NOV-2000: 2000US-0727344.
 XX (HYSE-) HYSEQ INC.
 XX Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
 PI Wang J, Wang Z, Wehrman T, Xu C, Xue AZ, Yang Y, Zhang J;
 PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
 XX WPI: 2001-442253/47.
 DE N-PSDB: AAI61315.
 XX Novel nucleic acids and polypeptides, useful for treating disorders
 PT such as central nervous system injuries.
 PS Example 2: SEQ ID NO 7090; 10078pp, English.
 XX The invention relates to human nucleic acids (AA157798-AA161369) and
 CC the encoded polypeptides (AA158642-AA162219) with nucleotide
 CC immunosuppressant and cytostatic activity. The polynucleotides are useful
 CC in gene therapy. A composition containing a polypeptide or polynucleotide
 CC of the invention may be used to treat diseases of the peripheral nervous
 CC system, such as peripheral nervous injuries, peripheral neuropathy and
 CC localised neuropathies and central nervous system diseases, such as
 CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
 CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
 CC utilisation of the activities such as: Immune system suppression,
 CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
 CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
 CC assays for receptor activity, arthritis and inflammation, leukaemias and
 CC C.N.S disorders.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification.
 SQ Sequence 580 AA;
 Query Match 68.1%; Score 47; DB 22; Length 580;
 Best Local Similarity 57.1%; Pred. No. 50;
 Matches 8; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 QY 1 EREKQMMREKEEL 14
 Db 495 QREKEQLQEKQEL 508
 RESULT 14
 AAB95603
 ID AAB95603 standard; Protein: 690 AA.
 XX AAB95603;
 AC AAB95603;
 DI 26-JUN-2001 (first entry)
 XX Human protein sequence SEQ ID NO.18294.
 DE Human, primet, detection, diagnosis, antisense therapy; gene therapy.
 KW human, primet, detection, diagnosis, antisense therapy; gene therapy.
 XX Homo sapiens.
 OS Homo sapiens.
 PN EP1074617-A2.
 XX 07-FEB-2001.
 PD 28-JUL-2000: 2000EP-0116136.
 PF

